Search

Your search keyword '"Lu, Zhen"' showing total 1,634 results
Start Over Author "Lu, Zhen" Search Limiters Academic (Peer-Reviewed) Journals
1,634 results on '"Lu, Zhen"'

15. Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer

Author

Young Han, Chae, Bedia, Jacob S., Yang, Wei-Lei, Hawley, Sarah J., Bergan, Lindsay, Hopper, Marika, Celestino, Joseph, Guo, Jing, Gornet, Terrie G., Soosaipillai, Antoninus, Yang, Hailing, Doskocil, Samantha D., Lokshin, Anna E., Handy, Beverly C., Diamandis, Eleftherios P., Moore, Richard G., Lu, Karen H., Lu, Zhen, Anderson, Karen S., Drescher, Charles W., Skates, Steven J., and Bast, Jr, Robert C.

Published
2024
Full Text
View/download PDF

20. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial

Author

Wang, De-Shen, Ren, Chao, Li, Shan-Shan, Fong, William Pat, Wu, Xiao-Jun, Xiao, Jian, Li, Bin-Kui, Zheng, Yun, Ding, Pei-Rong, Chen, Gong, Qiu, Miao-Zhen, Wang, Zhi-Qiang, Wang, Feng-Hua, Luo, Hui-Yan, Wang, Feng, Wang, Xiao-Zhong, Wang, Ling-Yun, Xie, De-Jin, Chen, Tao, Li, Li-Ren, Lu, Zhen-Hai, Zhai, Xiao-Hui, Liu, Tian-Shu, Yuan, Ying, Chen, Jia-Qi, Tan, Qiong, Pan, Zhi-Zhong, Wan, De-Sen, Zhang, Rong, Yuan, Yun-Fei, Xu, Rui-Hua, and Li, Yu-Hong

Subjects
Metastasis -- Physiological aspects, Pharmacology, Experimental, Colorectal cancer -- Drug therapy -- Physiological aspects, Drug therapy, Combination -- Testing -- Physiological aspects, Cancer -- Care and treatment -- Chemotherapy, Chemotherapy -- Testing -- Physiological aspects, Liver cancer -- Drug therapy -- Physiological aspects, Biological sciences
Abstract

Background It remains unclear whether intensification of the chemotherapy backbone in tandem with an anti-EGFR can confer superior clinical outcomes in a cohort of RAS/BRAF wild-type colorectal cancer (CRC) patients with initially unresectable colorectal liver metastases (CRLM). To that end, we sought to comparatively evaluate the efficacy and safety of cetuximab plus FOLFOXIRI (triplet arm) versus cetuximab plus FOLFOX (doublet arm) as a conversion regimen (i.e., unresectable to resectable) in CRC patients with unresectable CRLM. Methods and findings This open-label, randomized clinical trial was conducted from April 2018 to December 2022 in 7 medical centers across China, enrolling 146 RAS/BRAF wild-type CRC patients with initially unresectable CRLM. A stratified blocked randomization method was utilized to assign patients (1:1) to either the cetuximab plus FOLFOXIRI (n = 72) or cetuximab plus FOLFOX (n = 74) treatment arms. Stratification factors were tumor location (left versus right) and resectability (technically unresectable versus [greater than or equal to]5 metastases). The primary outcome was the objective response rate (ORR). Secondary outcomes included the median depth of tumor response (DpR), early tumor shrinkage (ETS), R0 resection rate, progression-free survival (PFS), overall survival (not mature at the time of analysis), and safety profile. Radiological tumor evaluations were conducted by radiologists blinded to the group allocation. Primary efficacy analyses were conducted based on the intention-to-treat population, while safety analyses were performed on patients who received at least 1 line of chemotherapy. A total of 14 patients (9.6%) were lost to follow-up (9 in the doublet arm and 5 in the triplet arm). The ORR was comparable following adjustment for stratification factors, with 84.7% versus 79.7% in the triplet and doublet arms, respectively (odds ratio [OR] 0.70; 95% confidence intervals [CI] [0.30, 1.67], Chi-square p = 0.42). Moreover, the ETS rate showed no significant difference between the triplet and doublet arms (80.6% (58/72) versus 77.0% (57/74), OR 0.82, 95% CI [0.37, 1.83], Chi-square p = 0.63). Although median DpR was higher in the triplet therapy group (59.6%, interquartile range [IQR], [50.0, 69.7] versus 55.0%, IQR [42.8, 63.8], Mann-Whitney p = 0.039), the R0/R1 resection rate with or without radiofrequency ablation/stereotactic body radiation therapy was comparable with 54.2% (39/72) of patients in the triplet arm versus 52.7% (39/74) in the doublet arm. At a median follow-up of 26.2 months (IQR [12.8, 40.5]), the median PFS was 11.8 months in the triplet arm versus 13.4 months in the doublet arm (hazard ratio [HR] 0.74, 95% CI [0.50, 1.11], Log-rank p = 0.14). Grade [greater than or equal to] 3 events were reported in 47.2% (35/74) of patients in the doublet arm and 55.9% (38/68) of patients in the triplet arm. The triplet arm was associated with a higher incidence of grade [greater than or equal to] 3 neutropenia (44.1% versus 27.0%, p = 0.03) and diarrhea (5.9% versus 0%, p = 0.03). The primary limitations of the study encompass the inherent bias in subjective surgical decisions regarding resection feasibility, as well as the lack of a centralized assessment for ORR and resection. Conclusions The combination of cetuximab with FOLFOXIRI did not significantly improve ORR compared to cetuximab plus FOLFOX. Despite achieving an enhanced DpR, this improvement did not translate into improved R0 resection rates or PFS. Moreover, the triplet arm was associated with an increase in treatment-related toxicity. Trial Registration ClinicalTrials.gov Identifier: NCT03493048., Author(s): De-Shen Wang 1, Chao Ren 1, Shan-Shan Li 2, William Pat Fong 1, Xiao-Jun Wu 3, Jian Xiao 2,4, Bin-Kui Li 5, Yun Zheng 5, Pei-Rong Ding 3, Gong [...]

Published
2024
Full Text
View/download PDF

42. Transportation scheduling for modules used in modular integrated construction.

Author

Huiwen Wang, Liang Liao, Wen Yi, and Lu Zhen

Subjects
MODULAR construction, TRANSPORTATION schedules, MATHEMATICAL programming, INTEGER programming, TRANSPORTATION costs
Abstract

Modular integrated construction (MiC) is an innovative construction method that is widely used in practice, but high transportation cost is an obstacle to its wider implementation. This paper is motivated by the real-world need for a scientific approach for MiC transport scheduling, and addresses the practical problem of how to achieve on-time door-to-door MiC delivery in an economical manner. An innovative integer programming model is formulated with the objective of minimising the total transportation costs, including trailer rental, fuel costs, and worker salaries. A case study based on Hong Kong data validates that the developed model can be efficiently solved for problems of practical size. The results also demonstrate that the derived MiC schedule plan can reduce transportation costs by 58.7% compared with a just-in-time (JIT) strategy, thus bringing great economic benefits to off-site construction practitioners. Useful managerial implications related to on-site MiC storage areas are derived through sensitivity analysis. Overall, this paper sets the ground for the application of mathematical programming methodology to the off-site construction field. Future research may be devoted to MiC transport scheduling under uncertainty. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results